The U.S. Food and Drug Administration (FDA) has approved a pill version of the popular weight-loss drug Wegovy, marking a significant advancement in the treatment of obesity. This daily oral medication is the first of its kind to be available for individuals seeking to manage their weight, offering a new alternative to traditional injectable treatments.
The approval places Novo Nordisk ahead of competitor Eli Lilly, whose oral drug orforglipron is still under FDA review. Both medications are classified as GLP-1 drugs and function similarly to existing injectables by mimicking a natural hormone that regulates appetite and satiety. Recent years have seen a surge in the usage of these treatments for obesity, a condition that affects approximately 100 million people in the United States alone.
Wegovy pills are anticipated to be available to patients within weeks, according to company representatives. Experts believe that the introduction of oral medications could significantly broaden access to obesity treatments and potentially lower costs. A survey conducted by the Kaiser Family Foundation (KFF) revealed that around 12.5% of Americans have used injectable GLP-1 drugs, but many struggle with the high costs associated with these treatments.
Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital, emphasized the importance of making weight-loss options available to a wider demographic. “There’s an entire demographic that can benefit from the pills,” she stated, highlighting the need for more accessible treatment options beyond just the race to market.
The newly approved oral Wegovy contains 25 milligrams of semaglutide, the same active ingredient found in the injectable versions of Wegovy and Ozempic, as well as in Rybelsus, a lower-dose pill approved for diabetes treatment in 2019. In clinical trials, participants using the oral form of Wegovy experienced an average weight loss of 13.6% over approximately 15 months, closely matching the 15% average weight loss reported for those using the injectable version.
Among the participants was Chris Mertens, a pediatric lung doctor from Menomonee Falls, Wisconsin, who joined the trial in 2022 and successfully lost around 40 pounds. He noted that the medication effectively reduced his appetite and intrusive food thoughts, allowing him to miss meals without realizing it.
In comparison, participants taking the highest dose of orforglipron lost an average of 11.2% of their body weight over nearly 17 months, while those on a placebo experienced a mere 2.1% loss. However, both pills fell short of the results achieved with Lilly’s Zepbound, which targets two gut hormones and led to an average weight loss of 21%.
While both oral options offer convenience, the Wegovy pill must be taken with a small amount of water on an empty stomach, requiring a 30-minute wait before consuming anything else. This design helps prevent the drug from being degraded in the stomach before it can be absorbed. In contrast, Lilly’s orforglipron does not have such restrictions.
The production of oral medications is typically less expensive than injectable forms, raising hopes that the cost of these new treatments may be lower than existing options. Earlier this year, the Trump administration engaged with drug manufacturers to negotiate reduced prices for GLP-1 drugs, which can exceed $1,000 per month. Novo Nordisk announced that the starting monthly dose of Wegovy will be priced at $149 through select providers, with further pricing details expected in January.
It remains uncertain whether patients will prefer daily pills or weekly injections. While some individuals are averse to needles, others are comfortable with the routine of injections. Mertens, for instance, chose to switch to the injectable Zepbound after regaining weight following the Wegovy trial, appreciating the discipline of taking a daily pill. “It was a little bit of an intentional routine and a reminder of today I’m taking this so that I know my choices are going to be affected for the day,” he explained.
Dr. Angela Fitch, an obesity expert and chief medical officer at knownwell, underscored that the key factor in the success of weight-loss medications lies in their affordability and accessibility. “It’s all about the price,” she asserted, emphasizing the crucial need for effective treatments at reasonable costs.
The approval of the Wegovy pill represents a pivotal moment in the landscape of obesity treatment, potentially transforming access for millions seeking effective weight management solutions.
